Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 7.79 -0.23 (2.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.02 | 52 Week High | $10.98 | |||
| Open | $7.96 | 52 Week Low | $1.63 | |||
| Day High | $8.02 | P/E | N/A | |||
| Day Low | $7.74 | EPS | $-0.68 | |||
| Volume | 4,431,265 | |||||
